A. Hutchaleelaha

发表

1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 2: A survey of P4 motifs.

B. Zhu, A. Arfsten, R. Scarborough, 2004, Bioorganic & medicinal chemistry letters.

Long-Term Dosing in Sickle Cell Disease Subjects with GBT440, a Novel HbS Polymerization Inhibitor

K. Bridges, K. Dufu, J. Howard, 2016 .

Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa.

J. Leeds, P. Conley, M. Karbarz, 2017, Blood advances.

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet Alfa (PRT064445), An Antidote For Fxa Inhibitors

S. Connolly, P. Conley, M. Karbarz, 2013 .

Increased hemoglobin–oxygen affinity ameliorates bleomycin‐induced hypoxemia and pulmonary fibrosis

K. Dufu, Qingbang Xu, Chien-Ming Li, 2016, Physiological reports.

GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half‐life in a murine model of sickle cell disease

S. Almo, Y. Patskovsky, K. Dufu, 2016, British journal of haematology.

A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.

K. Dufu, J. Howard, P. Telfer, 2019, Blood.

Simple apparatus for serial blood sampling in rodents permitting simultaneous measurement of locomotor activity as illustrated with cocaine.

J. Sukbuntherng, M. Mayersohn, A. Hutchaleelaha, 1997, Journal of pharmacological and toxicological methods.

Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin

C. Johnson, S. Almo, Lan Hua, 2017, ACS medicinal chemistry letters.

GBT1118, a compound that increases the oxygen affinity of hemoglobin, improves survival in murine hypoxic acute lung injury.

J. Bastarache, L. Ware, K. Dufu, 2018, Journal of applied physiology.

Abstract 10: Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Pharmacokinetic and Pharmacodynamic Study of PRT064445, a Universal Antidote for Factor Xa Inhibitors

M. Karbarz, M. Crowther, J. Curnutte, 2013 .

Sensitive enantiomer-specific high-performance liquid chromatographic analysis of methamphetamine and amphetamine from serum using precolumn fluorescent derivatization.

M. Mayersohn, A. Hutchaleelaha, H. Chow, 1994, Journal of chromatography. B, Biomedical applications.

Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease

C. Washington, A. Hutchaleelaha, D. Oksenberg, 2019, British journal of clinical pharmacology.

Influence of activated charcoal on the disposition kinetics of methamphetamine enantiomers in the rat following intravenous dosing.

M. Mayersohn, A. Hutchaleelaha, 1996, Journal of pharmaceutical sciences.

Inhibitory effect of 4-methylpyrazole on antipyrine clearance in rats.

M. Mayersohn, A. Hutchaleelaha, H. Chow, 1992, Life sciences.

Monday, 27 August 2012

V. V. Ivanenko, E. A. Medvedeva, Michail I. Papafaklis, 2012 .

Anthranilamide-based N,N-dialkylbenzamidines as potent and orally bioavailable factor Xa inhibitors: P4 SAR.

B. Zhu, Liang Bao, G. Park, 2009, Bioorganic & medicinal chemistry letters.

Disposition kinetics of d- and l-amphetamine following intravenous administration of racemic amphetamine to rats.

J. Sukbuntherng, M. Mayersohn, A. Hutchaleelaha, 1994, Drug metabolism and disposition: the biological fate of chemicals.

Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs.

B. Zhu, Liang Bao, A. Arfsten, 2004, Bioorganic & medicinal chemistry letters.

Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors with improved functional activity.

J. Woolfrey, B. Zhu, Liang Bao, 2004, Bioorganic & medicinal chemistry letters.

Parallel synthesis and structure-activity relationships of a series of highly potent, selective, and neutral factor Xa inhibitors.

J. Woolfrey, B. Zhu, A. Arfsten, 2004, Bioorganic & medicinal chemistry letters.

Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.

Lingyan Wang, Gary Park, James Kanter, 2009, Bioorganic & medicinal chemistry letters.

Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.

Keith Abe, Jin-Chen Yu, N. Giese, 2002, Journal of medicinal chemistry.

Identification of 4-piperazin-1-yl-quinazoline template based aryl and benzyl thioureas as potent, selective, and orally bioavailable inhibitors of platelet-derived growth factor (PDGF) receptor.

Jin-Chen Yu, N. Giese, A. Pandey, 2004, Bioorganic & medicinal chemistry letters.

N,N-Dialkylated 4-(4-arylsulfonylpiperazine-1-carbonyl)-benzamidines and 4-((4-arylsulfonyl)-2-oxo-piperazin-1-ylmethyl)-benzamidines as potent factor Xa inhibitors.

J. Woolfrey, B. Zhu, A. Arfsten, 2004, Bioorganic & medicinal chemistry letters.

Allometric Pharmacokinetic Scaling: Towards the Prediction of Human Oral Pharmacokinetics

Xiaochun Lou, Meihua Rose Feng, Richard R. Brown, 2000, Pharmaceutical Research.

Comparative Pharmacokinetics and Interspecies Scaling of Amphotericin B in Several Mammalian Species

M. Mayersohn, A. Hutchaleelaha, H. Chow, 1997, The Journal of pharmacy and pharmacology.

Enantiomeric determination of amphetamine and methamphetamine in urine by precolumn derivatization with Marfey's reagent and HPLC.

M. Mayersohn, A. Hutchaleelaha, D. Gilbert, 1998, Journal of analytical toxicology.

Separation and quantitation of the enantiomers of methamphetamine and its metabolites in urine by HPLC: precolumn derivatization and fluorescence detection.

J. Sukbuntherng, M. Mayersohn, A. Hutchaleelaha, 1995, Journal of analytical toxicology.

Preclinical safety and efficacy of andexanet alfa in animal models

P. Conley, J. Curnutte, S. Hollenbach, 2017, Journal of thrombosis and haemostasis : JTH.

A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa

P. Conley, P. Luan, M. Karbarz, 2013, Nature Medicine.

1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 3: Design, synthesis and SAR of orally bioavailable benzamidine-P4 inhibitors.

J. Woolfrey, B. Zhu, A. Arfsten, 2004, Bioorganic & medicinal chemistry letters.

Absorption, Metabolism and Excretion of GBT440, a Novel Hemoglobin S (HbS) Polymerization Inhibitor for the Treatment of Sickle Cell Disease (SCD), in Healthy Male Subjects

C. Washington, P. Rademacher, A. Hutchaleelaha, 2016 .

GBT440, a Potent Anti-Sickling Hemoglobin Modifier Reduces Hemolysis, Improves Anemia and Nearly Eliminates Sickle Cells in Peripheral Blood of Patients with Sickle Cell Disease

K. Dufu, J. Howard, P. Telfer, 2015 .

GBT440 Demonstrates High Specificity for Red Blood Cells in Nonclinical Species

B. Metcalf, A. Hutchaleelaha, D. Oksenberg, 2015 .

p ‐HYDROXYMETHAMPHETAMINE ENANTIOMER PHARMACOKINETICS AND METABOLISM IN RATS: ABSENCE OF N‐DEMETHYLATION

M. Mayersohn, A. Hutchaleelaha, 1997, Biopharmaceutics & drug disposition.

INITIAL INTRAVENOUS EXPERIENCE WITH PRT060128 (PRT128), AN ORALLY-AVAILABLE, DIRECT-ACTING, AND REVERSIBLE P2Y12 INHIBITOR

P. Conley, D. Phillips, P. Leese, 2007 .

Absorption, Metabolism and Excretion of GBT440, a Novel Hemoglobin S (HbS) Polymerization Inhibitor for the Treatment of Sickle Cell Disease (SCD), in Healthy Male Subjects

C. Washington, P. Rademacher, A. Hutchaleelaha, 2016 .